LAURA H. CYPHERS

This JAMA Patient Page describes liver cirrhosis, its signs and symptoms, potential complications, and treatment options.
Source: JAMA Online First

In this narrative medicine essay, a physician and single adoptive parent considers how orphaned children need not only material resources but love and specialized behavioral health care too.
Source: JAMA Online First

This Viewpoint examines the privacy concerns raised by medical uses of large language models, such as chatbots.
Source: JAMA Online First

This Viewpoint notes that as clinicians incorporate new AI tools (such as chatbots) into their practice, they must also remain vigilant of the risks these tools pose to other aspects of patient care such as privacy.
Source: JAMA Online First

This Viewpoint discusses the potential use of generative artificial intelligence (AI) in medical care and the liability risks for physicians using the technology, as well as offers suggestions for safeguards to protect patients.
Source: JAMA Online First

This Viewpoint discusses how regulators across the world should approach the legal and ethical challenges, including privacy, device regulation, competition, intellectual property rights, cybersecurity, and liability, raised by the medical use of large language models.
Source: JAMA Online First

This Viewpoint examines various aspects of using generative artificial intelligence (AI) in health care, including assisting with making clinical diagnoses, and the challenges that come with using AI, such as ensuring the accuracy of the clinical data on which AI makes its diagnoses.
Source: JAMA Online First

New draft guidance from the US Food and Drug Administration (FDA) includes a series of considerations for researchers designing clinical trials to investigate “classic psychedelics,” such as psilocybin, lysergic acid diethylamide (known as LSD), and methylenedioxymethamphetamine (known as MDMA). Psychedelics, many of which are currently classified as Schedule I controlled substances, have shown promise in recent years for the treatment of medical conditions such as depression, posttraumatic stress disorder, and substance use disorders, according to the FDA’s statement.
Source: JAMA Online First

Empagliflozin, a sodium-glucose cotransporter 2 inhibitor that lowers blood glucose levels by increasing the amount excreted in urine, was recently approved by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in children 10 years or older. The drug—marketed as Jardiance when administered alone and as Synjardy when combined with metformin—has already been approved for adults with type 2 diabetes. It is taken by mouth and can be used in addition to dietary changes and exercise to improve blood glucose levels, the FDA said in a statement. The approval is based on results from a randomized clinical trial involving 158 participants.
Source: JAMA Online First

A new initiative will address poverty’s role in cancer outcomes, the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), recently announced.
Source: JAMA Online First